What is Cellay?
Cellay, Inc. operates at the intersection of molecular diagnostics and high-throughput laboratory efficiency. The company is primarily recognized for its development of Same Day OligoFISH Probes, a breakthrough technology that utilizes short, chemically synthesized, and labeled oligonucleotides to facilitate rapid hybridization within a 5-10 minute window. By integrating cGMP manufacturing standards and isothermal processing, Cellay provides essential tools for researchers and clinical laboratories aiming to optimize their FISH (Fluorescence In Situ Hybridization) workflows. While the company maintains a clear regulatory stance that its products are not currently FDA-approved for clinical cancer diagnosis, its intellectual property portfolio and pending patent applications position it as a critical innovator in the research-use-only molecular biology market.
How much funding has Cellay raised?
Cellay has raised a total of $292K across 2 funding rounds:
Debt
$150K
Debt
$142K
Debt (2020): $150K with participation from PPP
Debt (2021): $142K led by PPP
Key Investors in Cellay
PPP
Public-Private Partnership
What's next for Cellay?
With the recent capital deployment, Cellay is poised to accelerate its operational scaling and market penetration. The strategic focus will likely shift toward expanding the reach of its OligoFISH platform, potentially targeting broader applications in genomic research and high-speed diagnostic screening. As the company navigates the complexities of late-stage growth, the emphasis on maintaining cGMP compliance and advancing its patent pipeline will be paramount. Investors are closely monitoring how this influx of financing will translate into increased adoption rates among institutional research partners and whether the firm will pursue further regulatory milestones to expand the utility of its probe technology beyond current research applications.
See full Cellay company page
